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Introduction
	
There are many factors which determine the drug com-
bination a patient is prescribed when diagnosed with multi-
ple myeloma. Some of  these factors include the patient’s 
age, level of  abnormal serum proteins, abnormal meta-
phase cytogenetics, and whether or not a patient is a candi-
date for autologous stem cell transplant (1). Thalidomide is 
a chemotherapeutic drug that acts by inhibiting angiogene-
sis. It is used alone or in combination with dexamethasone 
to treat recurrent or resistant multiple myeloma. Thalido-
mide is an immunomodulator as well as anti-angiogenic, is 
a known teratogen, and can increase the risk of  throm-
boembolic events, such as deep venous thrombosis (DVT) 
and pulmonary embolus (PE) (2).  Although many other 
classes of  chemotherapeutic drugs have been known to 
cause pulmonary disease, thalidomide as the inciting agent 
has been reported only once in the English literature (3) 
and twice in the world literature (4-5). 
Case Report
A 63-year-old male presented to the emergency depart-
ment with a two week history of  fever and shortness of  
breath. He had a history of  multiple myeloma, which was 
diagnosed two months prior to presentation. This diagnosis  
was confirmed by biopsy, showing a plasma cell clone with 
trisomy 11, tetrasomy 14, and IgH (Immunoglobulin 
Heavy) deletion. The patient had been on the thalidomide/
dexamethasone protocol for three weeks before presenting 
to the emergency department. He took thalidomide, 200 
mg per os (PO) daily. Dexamethasone 40 mg PO was taken 
for four days on, then four days off. A CT scan of  the chest 
was performed demonstrating nonspecific scattered ground 
glass opacities (Figure 1). All CT imaging on this patient 
was performed on a Siemens Somatom Sensation 64 (Sie-
mens Medical Solutions USA, Malvern, PA) using standard 
2 mm slice thickness, without intravenous (IV) contrast. 
Broad spectrum antibiotic therapy was initiated. A bron-
choalveolar lavage showed no evidence of  infection or neo-
plasm. There was no preponderance of  lymphocytes or 
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eosinophils to suggest a hypersensitivity reaction. Blood 
cultures were also negative and antibiotics were discontin-
ued at that time. The patient remained on the 
thalidomide/dexamethasone protocol when discharged 
home. 
Three weeks later, the patient presented to the hospital 
with acute shortness of  breath. The patient had not been 
taking dexamethasone for the two weeks prior to admission. 
On presentation, the patient denied associated chest pain, 
however the shortness of  breath was worse with exertion 
and was associated with weakness, anorexia and constipa-
tion. He denied having any hemoptysis, epistaxis or hema-
tochezia. He had a cardiovascular history, significant for 
paroxysmal atrial fibrillation, requiring ablation and subse-
quent pacemaker placement. He had no history of  throm-
boembolic disease.  Family history was non-contributory. 
He had an oxygen saturation of  86% at rest, with im-
provement to 95% on 4 liters/min oxygen. He was afebrile 
and had a respiratory rate of  18 breaths/min. His blood 
pressure and heart rate were normal. He was pale, but in 
no distress. His lung exam was normal. He had no periph-
eral edema. Laboratory work up was negative for infection, 
congestive heart failure or acute myocardial infarction.
A CT scan of  the chest (Figure 2) demonstrated extensive 
ground-glass attenuation throughout both lungs, which had 
significantly worsened since the previous CT scan. The 
differential diagnosis at that time included pulmonary 
edema, drug reaction, infection and hemorrhage. There 
was no evidence of  pulmonary embolism. 
The patient was admitted to the hospital and his 
thalidomide/dexamethasone protocol was discontinued.  
Solu-Medrol 100 mg IV was administered. The patient 
responded well, with improvement in his symptoms, and 
tolerated a decrease in supplemental oxygen to 2 liters/
min. A repeat CT scan obtained 48 hours after discontinu-
ing the thalidomide showed improvement in the ground-
glass opacities.  After 72 hours, the patient was discharged 
home with supplemental oxygen and a two week steroid 
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Figure 1. Axial CT demonstrating patchy, nonspecific 
ground glass opacities (arrows) in a patient who had started 
thalidomide therapy for multiple myeloma three weeks prior.
Figure 2. Coronal reformat (a) and axial (b) CT, 
performed three weeks after the CT shown in Figure 1, 
shows interval worsening of ground glass opacities (ar-
rows). Thalidomide therapy was discontinued at this time.
Figure 3. Axial CT obtained one month after discon-
tinuation of thalidomide therapy demonstrates near com-
plete resolution of pulmonary opacities.
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taper. One month after discharge a repeat CT scan was 
performed, revealing near resolution of  the pulmonary 
opacities (Figure 3).  
Discussion
Thalidomide, originally used as a sedative and hypnotic 
in the 1950’s, is a medication which inhibits angiogenesis 
and acts as an immunomodulator (3). More recently, tha-
lidomide has been added to a growing list of  new medica-
tions being used in the treatment of  multiple myeloma (6). 
This medication increases angiogenesis in the bone marrow 
of  patients with newly diagnosed, refractory or relapsed 
multiple myeloma. 
The therapeutic combination of  thalidomide with dex-
amethasone has been studied comparing its effectiveness 
against dexamethasone alone (7). Although the combina-
tion showed higher reduction in paraproteins, it also caused 
more toxic side effects, including deep venous thrombosis 
and pulmonary embolism (7). Acute drug-induced pulmo-
nary toxicity was not identified as a potential side effect. 
Interstitial lung disease is the most common pattern of  
drug-induced pulmonary injury and has been reported with 
over 350 drugs (8).  Drugs can cause a variety of  pathologi-
cal changes within the lung, including alveolar changes, due 
to edema or hemorrhage. They can also cause non-specific 
or eosinophilic pneumonia and even vasculitis (8).
Pulmonary ground glass opacity on CT is defined as a 
region of  increased attenuation that does not obscure the 
underlying vasculature (9). Ground glass opacity represents 
thickening of  the interstitium, incomplete filling of  the al-
veoli or a combination of  the two. The ground-glass opac-
ity demonstrated in our patient was nonspecific and could 
be seen with pulmonary edema, hemorrhage, drug toxicity, 
organizing pneumonia, mild pulmonary fibrosis, alveolar 
proteinosis, idiopathic interstitial pneumonia or infection. 
The clinical presentation of  the patient is critical in helping 
to determine the nature of  the underlying pathology (10).
Treatment of  drug-induced interstitial lung disease is 
cessation of  the inciting drug. Corticosteroid use can be 
considered depending on the clinical situation and the re-
sponse to withdrawal of  the offending drug.
Conclusion
Multiple myeloma is a complex disease process. New 
chemotherapy regimens have been extensively studied, but 
not all potential side effects have been clearly defined. Pa-
tients taking thalidomide who present with acute shortness 
of  breath should be evaluated for pulmonary embolism and 
pulmonary toxicity. Our patient responded well to supple-
mental oxygen and high dose steroids. Serial CT imaging 
should be considered to guide management and monitor 
resolution of  the transient toxic pulmonary effects.  
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